menu
    • menu
    [{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Soliqua\u00ae Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris and Biocon Biologic Announce Approval for First Interchangeable Biosimilar Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Insulin Glargine","moa":"Insulin receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tabuk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Pen Injection","sponsorNew":"Tabuk Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Tabuk Pharmaceuticals \/ Biocon"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Wins Court Decisions on Sanofi Appeals of Lantus\u00ae Patent Invalidations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee\u00ae (Insulin Glargine Injection), 100 units\/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Civica Rx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Civica Rx \/ GeneSys Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Civica Rx \/ GeneSys Biologics"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"HEC Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ HEC Group","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ HEC Group"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ypsomed","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ypsomed \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Ypsomed \/ Civica Rx"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"$3,335.0 million","upfrontCash":"$2,335.0 million","newsHeadline":"Biocon Biologics to Acquire Viatris\u2019 Biosimilars Assets for up to USD 3.335 billion in Stock and Cash","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":3.3399999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":3.3399999999999999,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Launches New Long-Acting Insulin Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Insulin Glargine

    Menu

    Insulin Glargine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France arrow
                            CPhI Worldwide, Milan
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Insulin Glargine,Lixisenatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sanofi Launches New Long-Acting Insulin Drug in India

                            Details : Soliqua is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. It is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes.

                            Brand Name : Soliqua

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 27, 2023

                            Lead Product(s) : Insulin Glargine,Lixisenatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France arrow
                            CPhI Worldwide, Milan
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Insulin Glargine,Lixisenatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Soliqua® Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin

                            Details : Participants were randomized to switch from their prior insulin to either Soliqua once daily or premixed insulin twice daily, with starting doses determined and adjusted weekly. Any metformin or SGLT-2i treatment was maintained through the study period.

                            Brand Name : Soliqua

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 28, 2021

                            Lead Product(s) : Insulin Glargine,Lixisenatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ypsomed

                            Switzerland arrow
                            Discovery on Target
                            Not Confirmed

                            Ypsomed

                            Switzerland arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Civica Rx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative

                            Details : Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and to ensure redundancy of supply, Ypsomed will provide injector dosing pens from their manufacturing...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 31, 2023

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Civica Rx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lannett Company, Inc.

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : HEC Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine

                            Details : Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer re...

                            Brand Name : Glaricon

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 31, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : HEC Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lannett Company, Inc.

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine

                            Details : The first study, which the FDA reviewed, suggested that the HEC insulin glargine product would be biosimilar to US-approved Lantus® (the reference biologic) in terms of meeting the study's pharmacokinetics (PK) and pharmacodynamics (PD) endpoints.

                            Brand Name : HEC-Glargine

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 29, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Civica Rx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : GeneSys Biologics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership

                            Details : Civica will produce three insulins – glargine, lispro and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively) – each of which will be available both in vials and prefilled pens.

                            Brand Name : Insulin Glargine-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 03, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : GeneSys Biologics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Viatris

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Biocon

                            Deal Size : $3,335.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

                            Details : The acquisition of biosimilars assets of Viatris significantly strengthens BBL’s position in providing affordable access to patients through its portfolio in diabetes, oncology, immunology and other non-communicable diseases including Semglee (Insulin ...

                            Brand Name : Semglee

                            Molecule Type : Peptide

                            Upfront Cash : $2,335.0 million

                            February 28, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Biocon

                            Deal Size : $3,335.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Viatris

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Biocon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (Insulin ...

                            Details : The Semglee® (insulin glargine injection), is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus and is packaged in prefille...

                            Brand Name : Semglee

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 18, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Biocon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Viatris

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations

                            Details : Decisions reaffirm Viatris' ability to provide patient access to interchangeable for the reference brand, Lantus®, allowing for substitution at the pharmacy counter. Semglee® is indicated to help control high blood sugar with type 1 diabetes and type 2...

                            Brand Name : Semglee

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            December 29, 2021

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tabuk Pharmaceuticals

                            Saudi Arabia arrow
                            Discovery on Target
                            Not Confirmed

                            Tabuk Pharmaceuticals

                            Saudi Arabia arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle...

                            Details : Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries...

                            Brand Name : Glaricon

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 07, 2021

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth